This is Google's cache of https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015186105. It is a snapshot of the page as it appeared on Jun 8, 2017 03:15:19 GMT.
The current page could have changed in the meantime. Learn more
These search terms are highlighted: torres baeza 
Full versionText-only versionView sourceTip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.
WO/2015/186105 METHOD FOR PRODUCING TOLEROGENIC DENDRITIC CELLS WITH SPECIFIC ANTIGENS AND USES THEREOF

Search International and National Patent Collections

1. (WO2015186105) METHOD FOR PRODUCING TOLEROGENIC DENDRITIC CELLS WITH SPECIFIC ANTIGENS AND USES THEREOF

Pub. No.:    WO/2015/186105    International Application No.:    PCT/IB2015/054267
Publication Date: Dec 10, 2015 International Filing Date: Jun 5, 2015
IPC: C12N 5/00
C12N 5/02
Applicants: PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
Inventors: LLANOS MUÑOZ, Carolina
KALERGIS PARRA, Alexis Mikes
VEGA TAPIA, Fabián Alejandro
TORRES BAEZA, Andy Igor
Title: METHOD FOR PRODUCING TOLEROGENIC DENDRITIC CELLS WITH SPECIFIC ANTIGENS AND USES THEREOF
Abstract:
The invention relates to a method for producing tolerogenic dendritic cells (tolDCs) with specific antigens, comprising the steps of: (a) culturing precursors of dendritic cells in an an animal-serum-free medium, using cytokines, IL-4 and GM-CSF, in order to differentiate same in dendritic cells; (b) producing apoptotic cells; (c) culturing the dendritic cells obtained in step (b) in the presence of compounds having anti-inflammatory activity; (d) co-culturing the dendritic cells from step (d) with the apoptotic cells from step (c), such as to stimulate the endocytosis of the apoptotic cells by the dendritic cells; (e) and, by means of identification based on phenotypic evaluation, determining the production of tolerogenic dendritic cells (tolDCs) with specific antigens. The invention also relates to the tolDC cells produced with said method and to the use of said tolDCs with specific antigens in the production of a drug suitable for the treatment of systemic lupus erythematosus.